SlidesetHIVSpanish HIV Clinical Forum 2017Toxicity and co-morbidities perspective- José Ignacio Bernardino, MDView Slideset
JMJosé MoltóMD, PhDSlidesetHIVSpanish HIV Clinical Forum 2017Pharmacological perspective- José Moltó, MD, PhDView Slideset
JSJonathan SchapiroMDSlidesetHIVSpanish HIV Clinical Forum 2017Reduced drug regimens, what’s the magic number: three, two or one? – Overview- Jonathan Schapiro, MDView Slideset
SlidesetHIVSpanish HIV Clinical Forum 2017Transmisión de mutaciones de resistencias a inhibidores de la integrasa- I. VicianaView Slideset
SlidesetHIVSpanish HIV Clinical Forum 2017Mutaciones a Inhibidores de la Integrasa en la vida real- I. VicianaView Slideset
SlidesetHIVSpanish HIV Clinical Forum 2017Primary Resistance to Integrase Strand-Transfer Inhibitors in Spain, 2015-2016 - M. CasadellàView Slideset
JAJose ArribasMDSlidesetHIVSpanish HIV Clinical Forum 20172016-2017 - Key Advances in HIV Treatment- José Arribas, MDView Slideset
SlidesetHIVSpanish HIV Clinical Forum 2017Prevalence of Transmitted Drug Resistance Mutations among Naïve HIV-infected patients (2014-2016) in Northwest Spain- B. Pernas SoutoView Slideset
SlidesetHIVSpanish HIV Clinical Forum 2017Update on HIV Transmitted and Acquired Integrase Resistance in Spain - Relevance to Routine Clinical Practice- Federico García, MDView Slideset
ASArun SanyalMD, MBBSSlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2017Integrated assessment of diabetes, cardiovascular and liver risks and its potential application in the clinical management of NAFLD- Arun Sanyal, MD, MBBSView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2017Navigating NASH biomarkers: From discovery to clinical practice- John Sninsky, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2017Next-Generation Sequencing (NGS) of two independent cohorts identifies eleven circulating miRNAs for diagnosis of NASH and fibrosis- Sven FrancqueView Slideset
